.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Citi
UBS
AstraZeneca
Cantor Fitzgerald
Johnson and Johnson
US Army
Cerilliant
Fish and Richardson
Medtronic

Generated: September 23, 2017

DrugPatentWatch Database Preview

Etravirine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for etravirine and what is the scope of etravirine freedom to operate?

Etravirine
is the generic ingredient in one branded drug marketed by Janssen R And D and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etravirine has one hundred and thirty-five patent family members in thirty-nine countries.

There are five drug master file entries for etravirine. Three suppliers are listed for this compound.

Summary for Generic Name: etravirine

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packagers: see list3
Bulk Api Vendors: see list71
Clinical Trials: see list47
Patent Applications: see list1,826
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:etravirine at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► SubscribeYY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Janssen R And D
INTELENCE
etravirine
TABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: etravirine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,638,932 2,4-disubstituted triazine derivatives► Subscribe
8,530,655HIV replication inhibiting pyrimidines► Subscribe
7,241,458Antiviral compositions► Subscribe
7,015,2212,4-disubstituted triazine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: etravirine

Country Document Number Estimated Expiration
African Regional IP Organization (ARIPO)1639► Subscribe
European Patent Office1129079► Subscribe
Australia7512700► Subscribe
Israel148801► Subscribe
Portugal1002795► Subscribe
Spain2258018► Subscribe
Czech Republic20020907► Subscribe
Germany69905683► Subscribe
South Korea20070036805► Subscribe
Israel143024► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ETRAVIRINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00004Denmark► Subscribe
2008016,C1002795Lithuania► SubscribePRODUCT NAME: ETRAVIRINUM; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
C033/2008Ireland► SubscribeSPC033/2008: 20090914, EXPIRES: 20230827
C/GB09/003United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023.
2009000003Germany► SubscribePRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
2008016Lithuania► SubscribePRODUCT NAME: ETRAVIRINUM; REG. NO/DATE: EU/1/08/468/001 20080828
7Finland► Subscribe
5/2009Austria► SubscribePRODUCT NAME: ETRAVIRIN UND DESSEN ADDITIONSSALZE
C0004France► SubscribePRODUCT NAME: ETRAVIRINE AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/468/001 DU 20080828; REGISTRATION NO/DATE AT EEC: EU/1/08/468/001 DU 20080828
528Luxembourg► Subscribe91528, EXPIRES: 20230828
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Colorcon
Queensland Health
Baxter
Dow
Fish and Richardson
Covington
Julphar
Harvard Business School
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot